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Abstract The cDNA from activated mutants of the homologous
transcription factors Pdr1p and Pdr3p was used to screen DNA
microarrays of the Saccharomyces cerevisiae complete genome.
Twenty-six overexpressed targets of the PDR1^3 and/or PDR3^
7 mutants were identified. Twenty-one are new targets, the
majority of which are of unknown function. In addition to well
known ABC transporters, these targets appear to be involved in
transport or in membrane lipids and cell wall biosyntheses.
Several of the targets seem to contribute to the cell defence
against a variety of stresses. Pdr1p and Pdr3p do not act
similarly on all targets. Unexpectedly, the expression of 23 other
genes appeared to be repressed in the PDR1^3 and/or PDR3^7
mutants. In contrast to the majority of the activated genes, none
of the repressed genes contains pleiotropic drug resistance
binding sites in their promoter.
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1. Introduction
In 1973, Rank et al. [1] reported the existence of a single
nuclear gene controlling the resistance of Saccharomyces cere-
visiae to 18 mitochondrial and non-mitochondrial inhibitors.
They proposed that this phenotype, called ‘pleiotropic drug
resistance’ (PDR), results from modi¢cation of plasma mem-
brane permeability [2]. In 1987, this gene was identi¢ed by
Balzi et al. [3] as PDR1, a new member of the Zn2Cys6 family
of transcription factors.
Another determinant of pleiotropic resistance was geneti-
cally identi¢ed in 1990 and called PDR5 [4]. Sequencing of
PDR5 in 1994 [5^7] showed that the encoded protein belongs
to the ABC transporter superfamily. It then became progres-
sively clear that Pdr5p is a plasma membrane e¥ux pump of
very broad speci¢city for amphiphilic drugs and that its ex-
pression is controlled by Pdr1p [5,8].
An outstanding feature of PDR1 is that its e⁄ciency as a
pleiotropic drug resistance e¡ector is considerably increased
by a series of dominant point mutations [5,9]. One of the most
powerful pleiotropic drug resistance mutations is PDR1^3,
derived from a strain originally isolated by Gue¤rineau et al.
[10]. This mutation dramatically increases the expression of
PDR5 mRNA [5,9,11,12], as well as that of other genes,
such as those encoding the ABC transporters Snq2p [11^13],
Yor1p [12,14], Pdr10p [12,15] and Pdr15p [12,15]. More im-
portantly, in the PDR1^3 mutant, the corresponding proteins
are highly overexpressed and apparently correctly tra⁄cked to
the plasma membrane in an active form, able to confer drug
resistance and to hydrolyze nucleoside triphosphates [11,12,
16].
In addition to Pdr1p, yeast contains a homologue called
Pdr3p [17], encoded by a gene originally identi¢ed and
mapped by Subik et al. [18,19]. Pdr3p and Pdr1p share iden-
tical binding sites on the promoters of PDR5, SNQ2 and
YOR1 [13,14,16,20^22]. Among other mutations, PDR3^7
markedly enhances pleiotropic drug resistance [23].
Genome analysis by DNA microarray hybridization analy-
sis is the tool of choice for identifying new targets of tran-
scription factors in yeast. This approach has been recently
validated by the study of the genes repressed in deletants of
the YAP1 gene [24]. We have used a similar technique to
identify targets of the PDR transcription factors using the
‘up’-mutations, PDR1^3 and PDR3^7, which considerably
amplify the sensitivity of the screen.
The identi¢cation of the overexpressed genes in the PDR1^
3 and PDR3^7 mutants greatly contributes to the delineation
of the complex network of genes involved in yeast pleiotropic
drug resistance. The understanding of the regulation of this
trait in S. cerevisiae should pave the way for the elucidation of
putative similar networks operating in pathogenic yeasts and
be relevant to the development of new fungicides.
2. Materials and methods
2.1. Strains and growth media
S. cerevisiae FY1679-28C/TDEC (MATa ura3-52 leu2v1 his3v200
trpv63 GAL2+ pdr1v: :TRP13 pdr3v: :HIS3) was the pdr1, pdr3 dou-
ble knock-out mutant used in this study. The strain was transformed
either with the PRS315: :pdr1^3 [9], or with the pFL36: :pdr3^7 [23].
Plasmid transformation with PRS315 or pFL387 empty vectors was
performed as a control. Yeast was grown on standard rich glucose
(YPD) medium or on synthetic complete (SC) media lacking appro-
priate amino acids for plasmid maintenance.
2.2. Hybridizations
Total RNA was extracted from cells grown in synthetic medium
containing 2% glucose and lacking appropriate amino acids for plas-
mid maintenance, harvested in the early exponential phase (107 cells/
ml) followed by mRNA puri¢cation using the Promega PolyATract
mRNA Isolation System. Fabrication of DNA microarrays, synthesis
of £uorescent labeled cDNA, hybridization to the microarrays and
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subsequent scanning were performed as previously described [24]. The
current protocols for all DNA microarray-related procedures are
available at http://cmgm.stanford.edu/pbrown/protocols.
2.3. Data analyses
Fluorescent images were analyzed using ScanAlyze software, avail-
able at http://rana.stanford.edu/software. Using the software of Eisen
et al. [25], genes were clustered hierarchically into groups on the basis
of the similarity of their expression pro¢les. The gene HXT2 and
YGR212w which yielded positive red signals were not considered sig-
ni¢cant because of a high similarity of HXT2 with numerous hexose
transporter gene sequences or because of putative interference of
YGR12w with a vicinal gene.
3. Results
3.1. The up-regulated genes
Total mRNA was isolated from exponentially growing
yeast cells and labeled with either the red £uorescent dye,
Cy5, in the case of the PDR1^3 or PDR3^7 mutant strains
or the green £uorescent dye, Cy3, in the case of the control
strain. In the latter, both wild type genes PDR3 or PDR1 were
deleted. The labeled cDNAs from each set were mixed and
hybridized to the gene microarrays of all available S. cerevi-
siae genes [24]. For each gene represented in the array, the
Cy5 £uorescence/Cy3 £uorescence ratio measured at the cor-
responding array element is a quantitative measurement of the
relative abundance of the transcript of that gene in the two
strains.
The mRNA levels for 26 genes were at least two-fold higher
in the PDR1^3 and/or PDR3^7 mutants (Fig. 1, red squares).
These genes could be grouped into three classes. The tran-
scription of 19 genes was activated by both mutations, but
to a greater extent by PDR1^3 than by PDR3^7. Another
group of four genes (PDR15, COS10, REV1 and FRE4)
showed greater activation by PDR3^7 than by PDR1^3. A
third group of three genes (YPL088w, YLL056w and
MET17) seems to be exclusively activated by the PDR1^3
mutants.
In vitro DNA binding studies and mutational analyses of
the promoters of known targets, such as PDR3, PDR5,
SNQ2, YOR1, PDR10, PDR15 and HXT11, have previously
identi¢ed several pleiotropic drug response elements called
PDREs [13,17,20^22,26,27] (Table 1). Fifteen of the 26 over-
expressed genes identi¢ed by the microarray hybridization ex-
periment as being activated by the PDR1^3 or PDR3^7 mu-
tations contain PDREs in their promoter (marked by the blue
balls in Fig. 1). When the sequences upstream of the 26
Pdr1p- or Pdr3p-activated genes were subjected to an un-
biased search for shared signature elements, a consensus se-
quence (C/TCCGC/TGGA/G), which perfectly matched the
known PDREs, was identi¢ed (Table 1).
However, several genes that were overexpressed in the
PDR1^3 or PDR3^7 mutants had no recognizable PDRE in
their promoters. It remains to be determined whether these
Fig. 1. Cluster image showing the di¡erent classes of gene expres-
sion pro¢les modi¢ed by PDR mutants. The PDR1^3 or PDR3^7
mutant alleles were carried on the centromeric plasmids pRS315
and pFL36, respectively, in the vPDR1vPDR3 double knock-out
strain FY1679-28c/TDEC. Genes whose transcript levels were in-
creased (red) or decreased (green) two-fold by the activating muta-
tions PDR1^3 (column 1) or PDR3^7 (column 2) were selected.
This subset of genes was clustered hierarchically on the basis of the
similarity of their expression pro¢les [25]. The blue circles in column
3 identify genes whose promoters (within 800 bp upstream of the
coding sequence) contain the consensus PDRE shown in Table 1.
Table 1
The pleiotropic drug response elements (PDRE) in promoters con-
trolled by Pdr1p and/or Pdr3p
PDRE-A T C C* G* C* G G* A*
PDRE-B T C C G T G* G A
PDRE-BP T C C A C G G A
PDRE-C T C C G C G C A
PDRE-D T C C G C G G G
Consensus T C C G/a C/t G G/c A/g
Asterisks denote residues which have been mutagenized and shown
to be necessary for PDRE function. Residues shown to be speci¢c
for each variant are underlined. This table is a compilation from
data reported in [20^22,26,27].
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genes contain Pdr1p or Pdr3p binding sites that di¡er from
the known PDREs or whether they are activated by an alter-
native factor subject to regulation by Pdr1p or Pdr3p.
The 26 genes that showed signi¢cant increased expression in
the PDR1^3 and PDR3^7 mutants can be divided into six
groups according to the putative or recognized functions of
their product (Table 2).
The ¢rst functional group is already well recognized. The
ABC transporter genes, PDR5 [5^7,16], YOR1 [12,14] and
SNQ2 [11,13,28], are known to be major determinants of
yeast multidrug resistance. The products of these three genes
mediate the e¥ux of structurally diverse hydrophobic com-
pounds [29]. The sequence of the PDR15 protein is very sim-
ilar to that of PDR5 ; its control by Pdr1p has previously been
reported [12,15], but its function as multidrug pump has not
yet been demonstrated.
The second group consists of three permeases. On the basis
of phylogenetic arguments, plasma membrane permeases have
been proposed to be involved in the cellular e¥ux of hydro-
phobic substrates [30]. However, none of the permeases listed
in Table 2 have been previously reported to be controlled by
PDR1 or PDR3. This is the case for the polyamine transport-
er, TP01 [31]. Tpo1p belongs to the DHA12 family (drug
proton antiport with 12 predicted transmembrane spans) of
the major facilitator superfamily and is involved in multidrug
resistance (do Valle Matta, Universite¤ de Louvain-la-Neuve,
Belgium, personal communication). Similarly, the gene RTA1,
which is involved in resistance to toxic sterol derivative [32], is
also a target of PDR1^3/PDR3^7. Very interestingly, another
new target, YORO49c, is a putative transporter homologous
to a gene involved in resistance to unknown toxic constituents
of sugar beet molasses [33]. It is thus tempting to suggest that
all the new permease-type targets of PDR1^3/PDR3^7 listed
in Table 2 are involved in the e¥ux of toxic, possibly hydro-
phobic, compounds.
Surprisingly some well characterized permease genes,
known to be regulated by PDR1 and PDR3, such as the
glucose transporter genes HXT9 and HXT11 [27] and the
multidrug transporter gene, FLR1 [34], were not found in
these analyses. The failure to detect by microarray analysis
these PDR1/PDR3 targets might be due to the limited sensi-
tivity of the DNA microarray.
The third group comprises two genes with known or pre-
dicted roles in lipid metabolism. We have recently shown that
PDR16 controls the phospholipid composition of the plasma
membrane which modi¢es the passive di¡usion of hydropho-
bic drugs across the plasma membrane, thereby modulating
multidrug resistance [35]. The IPT1 gene product, involved in
sphingosine synthesis [36], also modulates multidrug resis-
tance (Lambert, Universite¤ de Louvain-la-Neuve, Belgium,
personal communication). Thus, the lipid composition of the
plasma membrane is a determinant of multidrug resistance.
The fourth group consists of genes that encode proteins
with a weak sequence similarity to proteins involved in cell
wall metabolism. This suggests that the cell wall is not a
neutral barrier and that its composition, and possibly its per-
meability to hydrophobic compounds, might be modulated by
PDR1 or PDR3.
Table 2
Functional classi¢cation of gene products activated by the PDR1^3 and/or PDR3^7 mutations
Gene Function Phenotype
ABC transporters
YOR153w/PDR5 multidrug ATPase multidrug resistance
YGR281w/YOR1 multidrug ATPase multidrug resistance
YDR011w/SNQ2 multidrug ATPase multidrug resistance
YDR406w/PDR15 multidrug ATPase? ?
MFS and other permeases
YLL028w/TP01 MFS vacuolar polyamine transporter multidrug resistance
YOR049c transporter of unknown substrate? homology to molasses resistance
YGR213c/RTA1 transporter of unknown substrate? 7-aminocholesterol resistance
Lipid metabolism
YNL231c/PDR16 lipids synthesis multidrug resistance
YDR072c/IPT1 mannosyl diphosphorylinositol ceramide synthase multidrug resistance
Cell wall metabolism
YLR099c/ICT1 aromatic esterase azoles, benomyl resistance
YPL088w aryl-alcohol dehydrogenase calco£uor resistance
YGL028c/SCW11 soluble cell wall protein cell wall maintenance
YNR067c endo L-glucanase cell wall maintenance
Stress response
YNL160w/YGP1 secreted glycoprotein nutrient starvation-induced
YFR053c/HXK1 hexokinase 1 glucose starvation-induced
Y0L151w/GRE2 dihydro£avonol-reductase? osmotic stress-induced
YLR303w/MET17 O-acetyl homoserine sulfhydrylase osmotic stress-induced
YNR060w/FRE4 ferric reduction and transport oxidized iron-induced
YOR346w/REV1 DNA repair DNA damage-induced








The functions were compiled from the SGD, YPD and MIPS protein databases. The question marks (?) indicate unknown functions or func-
tions inferred only by sequence similarity.
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A coherent biochemical analysis of the genes classi¢ed in
the ¢fth group (called ‘stress’) is more di⁄cult. ‘Guilt by as-
sociation’ suggests that an investigation of the possible role of
these genes in defense against nutritional or other stresses is
warranted.
The last group, named ‘unknown’, contains six genes with-
out any known function. Of them, one of the strongest hyper-
activated new Pdr1/3 targets is YLR346c ; this gene, although
of unknown function, has a homologue, YGR035c, which is
also hyperinduced by PDR1 and PDR3 during late exponen-
tial growth (data not shown).
3.2. The down-regulated genes
The 23 genes for which transcript levels were at least two-
fold lower in either the PDR1^3 or the PDR3^7 mutant than
in their corresponding deletion mutants (green genes in Fig. 1)
can also be divided into three classes. The transcript levels for
10 genes were reduced in both the PDR1^3 and PDR3^7 mu-
tant strains, six genes showed reduced expression in the
PDR1^3 mutant, but were basically una¡ected by the
PDR3^7 mutation, while seven genes showed signi¢cantly re-
duced expression in the PDR3^7 mutant, but were essentially
una¡ected by the PDR1^3 mutation. Here again, Pdr1p and
Pdr3p act somewhat di¡erently.
None of the genes for which transcript levels were reduced
by the PDR1^3 or PDR3^7 mutations contained a recogniz-
able PDRE. The observed Pdr1p/Pdr3p-dependent repression
is therefore indirect and might be mediated by some as yet
unidenti¢ed repressors activated by Pdr1p and Pdr3p or by
another mechanism.
Since most of the genes that show PDR1/PDR3-dependent
repression of expression do not contain well-identi¢ed PDRE
elements in their promoters, their repression might not be
directly relevant to the PDR phenotype. However, it is inter-
esting to note that ¢ve of these genes (DUR3, MEP2, PDR12,
ZRT1 and FET4) code for membrane proteins involved in
diverse transport processes. Of these, PDR12 deserves a spe-
cial mention, since the expression of this ABC transporter,
which has been shown to confer resistance to permeable
weak acids [37] was clearly enhanced when PDR1/PDR3 are
absent. Two other repressed genes, FZF1 and PCL5 code for
regulatory elements involved in the developmental response to
phosphorus-limited growth. Thus, several aspects of this
Pdr1p/Pdr3p negative regulation seem to be related to trans-
port functions in response to the cell environment.
4. Discussion
In addition to the 49 genes for which the transcript level
changed, positively or negatively, by more than two-fold in
response to the PDR1^3 and PDR3^7 regulatory mutations,
several other genes showed smaller e¡ects on transcript levels ;
a list of these genes is available on the web site http://
www.biologie.ens.fr/yeast-publi.html. Some of these might
turn out to be signi¢cant targets when tested under di¡erent
physiological or genetic conditions. Indeed, the pattern of
PDR-regulated genes here reported is only valid for the re-
ported strains under the speci¢c growth conditions used (syn-
thetic glucose media and early exponential growth phase).
DNA microarray hybridization data must be considered
only as an initial global screening investigation. The expres-
sion levels of each newly detected target must be con¢rmed by
other methods. Such con¢rmation measurements are under
way (van den Hazel, Universite¤ de Louvain-la-Neuve, Bel-
gium, personal communication). For each target, it also re-
mains to be shown whether a single genomic copy of the wild
type PDR1 or PDR3 genes su⁄ces to signi¢cantly modulate
its expression under physiological conditions. Nevertheless,
almost all previously demonstrated positive targets of the
wild type PDR1 single copy gene have been con¢rmed by
the present work which markedly increase the sensitivity of
DNA microarray analysis by using up-regulating mutant.
Another transcription factor, the ‘leucine zipper’ Yap1p,
controls certain aspects of yeast multidrug resistance [38].
The major function of Yap1p seems to be oxidative stress
defense. At least three targets of YAP1 are also controlled
directly or indirectly by the PDR network [38]. The complex
interactions between Pdr1p, Pdr3p, Yap1 and other transcrip-
tion factors such as Yrr1p [39] are still to be experimentally
dissected for a total understanding of the regulation of pleio-
tropic drug resistance in yeast. For that purpose, the DNA
microarray approach used as presented here will probably be
helpful.
In conclusion, our data show that, under the tested condi-
tions, the Pdr1p/Pdr3p transcription factors renders the cell
resistant to chemical and nutritional stress in several ways
other than the well-known regulation of ABC e¥ux trans-
porters. We show that many of the genes overexpressed by
the PDR1^3 and PDR3^7 mutations encode proteins that
reduce intracellular accumulation of hydrophobic compounds.
At least four ABC transporters and three permeases seem to
be involved in the cellular e¥ux of these compounds. Modu-
lation of several enzymes involved in lipid synthesis and of
others possibly involved in cell wall metabolism, may modify
access of drugs to the plasma membrane. The coherence of
this complex strategy for conferring drug resistance, the ap-
parent functional redundancy of many genes involved and the
complexity of the various transport pathways is remarkable.
It will be interesting to investigate whether similar strategies
for defense against noxious chemical agents are employed by
other microorganisms, such as pathogenic yeasts and higher
eukaryotes.
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